DV
Dividend Vision

ORMP — Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. (ORMP)

Total return is 114771.8% over the past 22.4 years, 113819.7 points ahead of SPY at 952.1%. Its deepest 1-year drawdown was 23.9%.

Oramed Pharmaceuticals is a biopharmaceutical company focused on developing oral delivery technologies for therapeutic proteins. Its lead program is an oral insulin capsule in phase III clinical trials for diabetes treatment, and the company holds license agreements to commercialize oral vaccines for COVID-19. The company does not currently distribute dividends to shareholders.

ORMP key facts

Asset type
Stock
Asset class
Equity
Inception date
03/19/2004
Trailing yield
5.58%
Last close
$4.48
Market cap
$186,356,144
Average volume
156800.0
Last dividend
$0.2500
Ex-dividend date
01/16/2026
Payment date
01/26/2026
Beta
1.158
Payout ratio
0.1135
P/E ratio
1.0847
Forward P/E
0.0
EPS
$4.13